Latest Global Markets News

Compumedics has landed a $4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, pushing total MEG sales in China to $25 million and reinforcing its leadership in the Asian neuro-imaging market.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

Macquarie Group reported a 3% rise in net profit to A$1.655 billion for the half year ended September 2025, driven by strong growth in asset management and capital divisions. The group also extended its A$2 billion share buyback program and declared a solid interim dividend.

Perpetual Resources has certified exceptionally high caesium grades up to 28.3% Cs2O at its Morro Grande prospect in Brazil’s Lithium Valley, reinforcing its potential as a major critical minerals source.

Macquarie Group Limited reported a 3% increase in net profit to A$1.655 billion for the half year ended 30 September 2025, driven by robust performances in its asset management and capital segments. The Group’s diversified funding and strong capital position underpin its strategic growth and climate finance initiatives.

Macquarie Group Limited reported a 3% increase in half-year profit to $1.655 billion, driven by growth across its asset management, banking, commodities, and capital markets divisions. The group maintains robust capital and liquidity positions despite margin pressures and regulatory challenges.

Macquarie Group reported a solid half-year profit increase despite a sequential dip, boosted by strong asset management and capital markets performance. The group also extended its share buyback and declared a steady interim dividend.

Macquarie Group Limited reported a 3% increase in profit for the half year ended 30 September 2025, driven by strong performances in asset management and capital advisory, while declaring a 35% franked interim dividend of $2.80 per share.

Elementos Limited reports significant tungsten grade and recovery improvements at its Cleveland Project in Tasmania, driven by successful XRT ore sorting tests amid soaring tungsten prices.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

Goodman Group reports robust progress in Q1 FY26 with a $12.4 billion development pipeline dominated by data centres, reaffirming a 9% operating EPS growth forecast. The group is advancing logistics automation and expanding data centre capacity across key global markets.